Akari Therapeutics ADR (AKTX) Stock Price, Quote & News

Company Profile

Akari Therapeutics, Plc, an oncology company, develops next-generation antibody-drug conjugates (ADC) for cancer-killing toxins. Its lead payload is PH1 to disrupt the function of spliceosomes and to trigger an immune response that leads to additional cancer cell killing. The company's lead product candidate is AKTX-101, a preclinical stage trop2-targeting ADC that combines PH1 with the trop2 antibody to treat solid tumor cancer types, including lung, breast, colon, and prostate. Its payloads in...

Industry: Biotechnology

Sector: Healthcare

Phone: 929 274 7510

Fax: 929 274 7553

Website: www.akaritx.com

Address:

22 Boston Wharf Road, Floor 7, Boston, United States

topstockalerts Oct. 15 at 5:26 PM

Akari Therapeutics shares fell Wednesday after the oncology biotech announced a registered direct offering of American Depositary Shares (ADS) priced below market value. The company is selling 3,125,000 ADS at $0.80 each, with each ADS representing 2,000 ordinary shares—a discount to recent trading levels that likely triggered the drop. Akari will also issue unregistered warrants in a concurrent private placement: Series E warrants to purchase up to 3,125,000 ADS at $0.98 per share, exercisable after shareholder approval for five years, and Series F warrants with a 30-month term. The company expects to raise about $2.X.5 million in gross proceeds, with closing expected around October 16, 2025. Ladenburg Thalmann & Co. Inc. is acting as exclusive placement agent. $AKTX

0 · Reply

topstockalerts Oct. 15 at 5:26 PM

Akari Therapeutics shares fell Wednesday after the oncology biotech announced a registered direct offering of American Depositary Shares (ADS) priced below market value. The company is selling 3,125,000 ADS at $0.80 each, with each ADS representing 2,000 ordinary shares—a discount to recent trading levels that likely triggered the drop. Akari will also issue unregistered warrants in a concurrent private placement: Series E warrants to purchase up to 3,125,000 ADS at $0.98 per share, exercisable after shareholder approval for five years, and Series F warrants with a 30-month term. The company expects to raise about $2.5 million in gross proceeds, with closing expected around October 16, 2025. Ladenburg Thalmann & Co. Inc. is acting as exclusive placement agent. $AKTX

0 · Reply

coachmc Oct. 15 at 1:40 PM

$AKTX rough day. Looks like old rival Omer is celebrating on their good news

0 · Reply

OpenOutcrier Oct. 15 at 1:08 PM

$AKTX (-6.1% pre) Akari Therapeutics raises $2.X.5 million in direct offering https://ooc.bz/l/80608

0 · Reply

Bart69 Oct. 15 at 12:38 PM

$AKTX "Akari Therapeutics, Plc (NASDAQ:AKTX) (the "Company"), an oncology biotechnology company developing novel payload antibody drug conjugates (ADCs), today announced that it has entered into a definitive agreement for the issuance and sale of an aggregate of 3,125,000 of the Company's American Depositary Shares ("ADSs"), each representing 2,000 ordinary shares at a purchase price of $0.80 per ADS in a registered direct offering."

0 · Reply

Bart69 Oct. 10 at 2:05 PM

$AKTX Adding below 1 still. Not falling for shake outs.

0 · Reply

bohrsmodel Oct. 9 at 3:22 AM

$AKTX Lots of insider purchase and 2 key patents in Asia. Analyst Consensus. Strong Buy. Average Price Target: $4.53

0 · Reply

bohrsmodel Oct. 9 at 3:09 AM

$NXL positive clinical trial result and huge insider buy $AKTX secured 2 patent in Asia, lots of insider purchase $PSTV Agreement with United Healthcare. Analyst Price Forecast Suggests 1,132.22% Upside $ATHR.CSE Aether Catalyst Solutions Files Landmark Patent: A Game-Changer for Automotive Emissions and Precious Metal Markets. Imagine no more catalytic converters being stolen anymore. $BUX.CSE Patent approved and test run in Germany on 10,000 people to run lung cancer screening

0 · Reply

jennybaby Oct. 6 at 7:03 PM

$AKTX there is a sector rotation into biotech, especially the beaten up ones. And this turd is barely creeping up. 🤦🏼‍♀️🤦🏼‍♀️🤦🏼‍♀️

1 · Reply

stockscan Oct. 3 at 2:24 PM

$AKTX https://investor.akaritx.com/news-releases/news-release-details/akari-therapeutics-announces-abstract-accepted-oral-presentation

0 · Reply

Akari Therapeutics Announces Launch of CEO Corner Platform

Oct 15, 2025, 8:30 AM EDT - 12 days ago

Akari Therapeutics Announces $2.5 Million Registered Direct Offering

Oct 9, 2025, 8:45 AM EDT - 18 days ago

Akari Therapeutics Files Two New Patents for Immuno-Oncology Mode of Action for Novel ADC Platform Utilizing Spliceosome Modulating Payload PH1

Oct 3, 2025, 9:30 AM EDT - 24 days ago

Akari Therapeutics Announces Abstract Accepted for Oral Presentation at the 40th Annual Society for Immunotherapy of Cancer (SITC) Meeting

Sep 24, 2025, 8:45 AM EDT - 4 weeks ago

Akari Therapeutics' Preclinical Data Demonstrates the Potential of its Novel ADC Spliceosome Modulating Payload, PH1

Sep 17, 2025, 8:45 AM EDT - 5 weeks ago

Akari Therapeutics Announces Filing for New Patent for Novel ADC Platform Utilizing Spliceosome Payload PH1 for the Treatment of Cancer

Sep 10, 2025, 1:44 PM EDT - 6 weeks ago

Akari Therapeutics, Plc (AKTX) Discusses At Virtual Investor Closing Bell Series Call (Transcript)

Sep 5, 2025, 6:45 AM EDT - 7 weeks ago

Akari Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference

Sep 3, 2025, 8:30 AM EDT - 7 weeks ago

Akari Therapeutics to Participate in the Virtual Investor Closing Bell Series

Aug 14, 2025, 9:15 AM EDT - 2 months ago

Akari Therapeutics to Present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech

Jul 29, 2025, 9:15 AM EDT - 3 months ago

Akari Therapeutics Releases Virtual Investor “What This Means” Segment

Jul 23, 2025, 8:55 AM EDT - 3 months ago

Akari Therapeutics Continues Key Research on its Novel Antibody Drug Conjugate Payload PH1 to Further Demonstrate its Unique Ability to Target Cancers Fueled by Oncogenic Drivers

Jul 22, 2025, 8:45 AM EDT - 3 months ago

Akari Therapeutics Participates in the Virtual Investor “What's Your Story” Summer Spotlight On-Demand Conference

Jun 25, 2025, 9:00 AM EDT - 4 months ago

Akari Therapeutics Releases Virtual Investor “What This Means” Segment Highlighting its Recently Granted India Patent

Jun 18, 2025, 8:50 AM EDT - 4 months ago

Akari Therapeutics Bolsters Global IP Estate for its Novel Antibody Drug Conjugate (ADC) Immuno-Oncology Payload, PH1, with Recent Granting of Patent Protection Across India

May 29, 2025, 9:15 AM EDT - 5 months ago

Akari Therapeutics Releases “Meet the Team” Video Featuring Recently Appointed Mark F. Kubik, Head of Business Development – Oncology

May 22, 2025, 9:00 AM EDT - 5 months ago

Akari Therapeutics to Present at LIVE! with Webull Corporate Connect: Virtual Biotech Investment Webinar

May 19, 2025, 8:00 AM EDT - 5 months ago

Corbus Pharmaceuticals Names Industry Veteran Rachelle Jacques as Board Chair

CRBP QURE

May 15, 2025, 8:05 AM EDT - 5 months ago

Akari Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update

May 1, 2025, 8:45 AM EDT - 6 months ago

Akari Therapeutics Appoints Mark F. Kubik as Head of Business Development - Oncology

Apr 22, 2025, 9:05 AM EDT - 6 months ago

Akari Therapeutics Releases Welcome Video from Newly Appointed Chief Executive Officer, Abizer Gaslightwala

Mar 20, 2025, 8:35 AM EDT - 7 months ago

Akari Therapeutics Appoints Biotechnology Industry Leader, Abizer Gaslightwala, as President and Chief Executive Officer

Mar 3, 2025, 9:00 AM EST - 8 months ago

Akari Therapeutics Announces $7.6 Million Private Placement Offering Led by Existing Shareholders and Insiders Priced at the Market Under Nasdaq Rules

Feb 19, 2025, 9:00 AM EST - 8 months ago

Akari Therapeutics Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference

Feb 3, 2025, 8:00 AM EST - 9 months ago

Akari Therapeutics Joins Webull Corporate Connect Service Platform

Dec 18, 2024, 8:51 AM EST - 11 months ago

Akari Therapeutics Announces Key Leadership Appointments

Dec 16, 2024, 9:05 AM EST - 11 months ago

Akari Therapeutics Appoints Torsten Hombeck, Ph.D. as Chief Financial Officer

Nov 14, 2024, 4:15 PM EST - 1 year ago

Akari Therapeutics Announces Successful Completion of Merger of Akari Therapeutics and Peak Bio

Nov 8, 2024, 8:00 AM EST - 1 year ago

Akari Therapeutics Announces Shareholder Approval in Connection With Peak Bio, Inc. Merger

Aug 19, 2024, 4:15 PM EDT - 1 year ago

Akari Therapeutics Reports Second Quarter 2024 Financial Results and Recent Highlights

Aug 19, 2024, 8:00 AM EDT - 1 year ago

Akari Therapeutics Receives Positive and Constructive Pre-IND Feedback from US FDA for PAS-nomacopan in Treatment of Geographic Atrophy

May 16, 2024, 8:00 AM EDT - 1 year ago

Akari Therapeutics Reports First Quarter 2024 Financial Results and Recent Highlights

May 1, 2024, 8:01 AM EDT - 1 year ago

Samir R. Patel, M.D. Appointed Interim CEO for Akari Therapeutics

May 1, 2024, 8:00 AM EDT - 1 year ago

Akari Therapeutics and Peak Bio Announce Portfolio Prioritization Plan for Combined Go-Forward Merger Entity

Apr 15, 2024, 8:00 AM EDT - 1 year ago

Akari Therapeutics to Present PAS-Nomacopan Pre-Clinical Electroretinography (ERG) Data at ARVO 2024

Apr 1, 2024, 6:30 AM EDT - 1 year ago

Akari Therapeutics Reports Full-Year 2023 Financial Results and Recent Highlights

Mar 5, 2024, 8:00 AM EST - 1 year ago

Akari Therapeutics and Peak Bio Announce Definitive Agreement to Merge as Equals Creating an Expanded Pipeline That Features a Novel Antibody Drug Conjugate (ADC) Toolkit

Jan 2, 2024, 8:00 AM EST - 1 year ago

Akari Therapeutics Announces Existing Investors Support the Company Through a $2 Million Private Placement Financing

Dec 14, 2023, 8:00 AM EST - 2 years ago

Akari Therapeutics to Present at Biotech Showcase 2024

Dec 1, 2023, 8:00 AM EST - 2 years ago

Akari Therapeutics Appoints Experienced Life Sciences Entrepreneur Samir R. Patel, M.D.

Nov 16, 2023, 8:00 AM EST - 2 years ago

Akari Therapeutics Presents Poster on Progress in Pre-Clinical Development of Long-Acting PAS-Nomacopan as a Potential Treatment for Geographic Atrophy at the 4th Annual Dry AMD Therapeutic Development Conference

Nov 6, 2023, 8:00 AM EST - 2 years ago

Akari Therapeutics to Present a Poster on Pre-Clinical Development of Long-Acting PAS-Nomacopan as a Potential Treatment for Geographic Atrophy at the 4th Annual Dry AMD Therapeutic Development Conference

Sep 29, 2023, 8:00 AM EDT - 2 years ago

Akari Therapeutics Reports First Half 2023 Financial Results and Highlights

Sep 27, 2023, 8:00 AM EDT - 2 years ago

Akari Therapeutics to Present at Emerging Growth Conference

Sep 21, 2023, 8:00 AM EDT - 2 years ago

Akari Therapeutics Announces Existing Investors Support the Company Through a $2 Million Private Placement Financing, Company Also Receives $2.5 Million U.K. R&D Tax Credit

Sep 19, 2023, 8:00 AM EDT - 2 years ago

Akari Therapeutics to Host Key Opinion Leader Webinar on Hematopoietic Stem Cell Transplant-Related Thrombotic Microangiopathy (HSCT-TMA) and the Potential of Nomacopan to Address Significant Unmet Needs

Sep 5, 2023, 8:00 AM EDT - 2 years ago

Akari Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement

Aug 18, 2023, 8:00 AM EDT - 2 years ago

Akari Therapeutics Announces Establishment of Boston U.S. Headquarters Office to Support Expanding Operations and Start of Registrational Phase 3 Clinical Trials

Aug 15, 2023, 8:00 AM EDT - 2 years ago

Akari Therapeutics, Plc Announces ADS Ratio Change

topstockalerts Oct. 15 at 5:26 PM

0 · Reply

topstockalerts Oct. 15 at 5:26 PM

Akari Therapeutics shares fell Wednesday after the oncology biotech announced a registered direct offering of American Depositary Shares (ADS) priced below market value. The company is selling 3,125,000 ADS at $0.80 each, with each ADS representing 2,000 ordinary shares—a discount to recent trading levels that likely triggered the drop. Akari will also issue unregistered warrants in a concurrent private placement: Series E warrants to purchase up to 3,125,000 ADS at $0.98 per share, exercisable after shareholder approval for five years, and Series F warrants with a 30-month term. The company expects to raise about $2.5 million in gross proceeds, with closing expected around October 16, 2025. Ladenburg Thalmann & Co. Inc. is acting as exclusive placement agent. $AKTX

0 · Reply

coachmc Oct. 15 at 1:40 PM

$AKTX rough day. Looks like old rival Omer is celebrating on their good news

0 · Reply

OpenOutcrier Oct. 15 at 1:08 PM

$AKTX (-6.1% pre) Akari Therapeutics raises $2.X.5 million in direct offering https://ooc.bz/l/80608

0 · Reply

Bart69 Oct. 15 at 12:38 PM

0 · Reply

Bart69 Oct. 10 at 2:05 PM

$AKTX Adding below 1 still. Not falling for shake outs.

0 · Reply

bohrsmodel Oct. 9 at 3:22 AM

$AKTX Lots of insider purchase and 2 key patents in Asia. Analyst Consensus. Strong Buy. Average Price Target: $4.53

0 · Reply

bohrsmodel Oct. 9 at 3:09 AM

0 · Reply

jennybaby Oct. 6 at 7:03 PM

$AKTX there is a sector rotation into biotech, especially the beaten up ones. And this turd is barely creeping up. 🤦🏼‍♀️🤦🏼‍♀️🤦🏼‍♀️

1 · Reply

stockscan Oct. 3 at 2:24 PM

$AKTX https://investor.akaritx.com/news-releases/news-release-details/akari-therapeutics-announces-abstract-accepted-oral-presentation

0 · Reply

2pumps1dump Sep. 29 at 3:01 PM

$AKTX

0 · Reply

StockScanners Sep. 26 at 5:16 AM

$AKTX reached 1.24

0 · Reply

Tidewater1980 Sep. 26 at 2:16 AM

$LAC $AKTX Bring The Juice

0 · Reply

2pumps1dump Sep. 25 at 2:59 PM

$AKTX still early

0 · Reply

SMARTR8 Sep. 25 at 2:16 PM

$AKTX BANGGGG 🤝🤝🤝✅️✅️✅️✅️⬇️⬇️⬇️⬇️

0 · Reply

2pumps1dump Sep. 25 at 8:50 AM

$AKTX 🧐 come on.

0 · Reply

StockScanners Sep. 25 at 1:07 AM

$AKTX keep watch if this holds above 1.05

0 · Reply

BearishAlgo Sep. 25 at 1:03 AM

Wednesday 2025-09-24 Recap: $OFAL -5.71% ❌ $PEPG -7.11% ❌ $TKNO -2.56% ❌ $AKTX +6.67% ✅ $CRE +20.65% ✅

0 · Reply

BearishAlgo Sep. 25 at 12:36 AM

$AKTX Rejected the zone, never broke the upper boundary, dropped from 1.20 to 1.05, closed at 1.12. NEWS: phase1 preclinical data release

0 · Reply

IntraTrades Sep. 25 at 12:02 AM

$SLNH 60.18% $DBGI 43.75% $PEPG 36.41% $AKTX 35.27% $ATCH 30.86%

0 · Reply

jennybaby Sep. 24 at 11:09 PM

$AKTX this is the first time in bazillions that AKTX held the gains with 3.67 mill shares traded. I hope to see some continuation. I did unload 5k shares for a puny profit and I am still holding 11.2k shares. Peanuts compared to what I had once and I am totally cool with that.

0 · Reply

VolcanicTrades Sep. 24 at 10:44 PM

$AKTX keep an eye. Called a pretty close bottom on $CDLX as well

0 · Reply

Market Cap	24.14M
Revenue (ttm)	0.00
Net Income (ttm)	-19.79M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.03

Volume	206,861
Avg Vol	248,416
Day's Range	N/A - N/A
Shares Out	32.62M
Stochastic %K	7%
Beta	0.36
Analysts	Strong Sell
Price Target	$4.53